Elanco Leader Joins Neurizon to Boost ALS Drug Program
MELBOURNE, Australia – Nov. 26, 2025 — Neurizon Therapeutics (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotech firm...
ALS
Advertisement
FDA Grants Orphan Drug Status to Cellenkos’ CK0803 for ALS Treatment
HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
AB Science Secures €2.8 Million in Private Placement to Advance Clinical Pipeline
PARIS, October 17, 2025 AB Science S.A., a biopharmaceutical company focused on discovering, developing, and marketing protein kinase inhibitors,...
VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
Advertisement
